## TECH: Bio-Techne Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.0% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($55.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Bio-Techne Corp (TECH) Stock Price History & Data**
- Source: Traders Union | 20251227T060859 | Neutral | Relevance: 100%
- This article provides a comprehensive history of Bio-Techne Corp (TECH) stock price and market capitalization data. It includes current stock performance, 52-week highs and lows, and historical yearly data for open, high, low, close, and return. The piece also offers a brief overview of recent news concerning other major stocks.

**2. Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference**
- Source: Quantisnow | 20251224T070855 | Somewhat-Bullish | Relevance: 100%
- Bio-Techne Corporation announced that its President and CEO, Kim Kelderman, will present at the 2026 J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be webcast live on Bio-Techne's investor relations website. Bio-Techne is a global life sciences company providing tools and reagents for research and diagnostics.

**3. Assenagon Asset Management S.A. Invests $2.75 Million in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251224T090153 | Somewhat-Bullish | Relevance: 100%
- Assenagon Asset Management S.A. has acquired a new position of 49,446 shares, valued at $2.75 million, in Bio-Techne Corp (NASDAQ:TECH) during the third quarter. Other institutional investors have also adjusted their holdings in the biotechnology company, which reported Q3 EPS in line with estimates but revenue slightly below expectations. Bio-Techne pays a quarterly dividend of $0.08, has a P/E of about 120.9, and carries a consensus "Moderate Buy" rating with a target price near $71 from analysts.

**4. Voya Investment Management LLC Has $7.04 Million Holdings in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251225T132833 | Neutral | Relevance: 100%
- Voya Investment Management LLC significantly reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 71.9% in Q3, selling 324,328 shares and retaining 126,453 shares valued at approximately $7.04 million. Institutional ownership of Bio-Techne remains very high at 98.95%, with other major institutional investors like Select Equity Group and Norges Bank holding substantial positions. Bio-Techne currently trades near $58.71, has a market cap of $9.15 billion, and pays a quarterly dividend of $0.08, while analysts have a consensus "Moderate Buy" rating with a price target of $71.00.

**5. BTIG reiterates Buy rating on MDxHealth stock, maintains $7 price target**
- Source: Investing.com Australia | 20251224T120855 | Neutral | Relevance: 63%
- BTIG has reaffirmed its Buy rating and $7 price target for MDxHealth (NASDAQ:MDXH), anticipating accelerated revenue growth and improved EBITDA margins in 2026. The firm highlights MDxHealth's strong position in prostate diagnostics, particularly following the successful integration of its ExoDx acquisition, distinguishing it as an attractive small-cap growth and value stock. Despite a recent earnings miss, BTIG maintains confidence, noting the company's valuation is below peers and analyst consensus is a Strong Buy.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 27.3x stretched relative to 10% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 27.3 |
| Current P/E | 30.0 |
| YoY Growth | 10.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 3.0pp (needs >3.0% for momentum thesis). MRS_5 at 0.0% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). RSI neutral at 47. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.02% (CS: 74) | Neutral |
| RSI_14 | 47.4 | Neutral |
| MACD Histogram | -0.06 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 0.971x | Below |
| vs SMA200 | 1.073x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $59.22
- **Stop Loss:** $55.66 (6.0% risk)
- **Target:** $62.78 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 370
- **Position Value:** $21,911.40
- **Portfolio %:** 21.91%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*